A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

T. Boumpas, Dimitrios; Furie, Richard; Manzi, Susan; G. Illei, Gabor; J. Wallace, Daniel; E. Balow, James; Vaishnaw, Akshay; behalf of the BG9588 Lupus Nephritis Trial Group, on

doi:10.1002/art.10856

Public

A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

Published in Arthritis & Rheumatism • Feb 28, 2003

Authors:

Dimitrios T. Boumpas

Richard Furie

Susan Manzi

Abstract

OBJECTIVE: CD40-CD40 ligand (CD40L) interactions play a significant role in the production of autoantibodies and tissue injury in lupus nephritis. We performed an open-label, multiple-dose study to evaluate the safety, efficacy, and pharmacokinetics of BG9588, a humanized anti-CD40L antibody, in pat...

Subject

Medicine

Lupus nephritis

Proteinuria

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!